<div id="readability-page-1"><div><p>(MT Newswires) -- Yifan Pharmaceutical (SHE:002019) subsidiary Hefei Yifan Biological Pharmaceutical obtained drug registration from China's medical products administrator for isavuconazole sulfate for injection.</p><p> The broad-spectrum antifungal drug is used to treat infections such as aspergillosis and mucormycosis in adults, according to a filing with the Shanghai bourse.</p><p> The validity is until September 2030.</p><p>Shares of the pharmaceutical company were down 1% in recent trade.</p></div></div>

亿帆医药

<p>（MT Newswires）-- 亿帆医药（SHE:002019）子公司合肥亿帆生物医药获得中国医疗产品管理局的药物注册，批准注射用伊沙康唑硫酸盐。这种广谱抗真菌药物用于治疗成人的感染，如曲霉病和 mucormycosis。根据上海证券交易所的文件，该注册有效期至 2030 年 9 月。该制药公司的股票在最近的交易中下跌了 1%</p>

亿帆医药的子公司获得了抗真菌药物的监管批准